FABP4 and hepatocellular carcinoma: In a previous study from our hospital where most HCC patients carried HBV, FABP4 was low-expressed in tumor tissues compared with the adjacent tissue, and its expression as a favorable biomarker was significantly associated with the tumor size, portal vein tumor thrombus, recurrence-free survival and overall survival [29].